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A B S T R A C T
Introduction. Thirty million men in the United States suffer from erectile dysfunction (ED) and this number is
expected to double by 2025. Considered a major public health problem, which seriously affects the quality of life of
patients and their partners, ED becomes increasingly prevalent with age and chronic smoking is a major risk factor
in the development of ED.
Aim. To review available evidence concerning the effects of cigarette smoking on vascular changes associated with
decreased nitric oxide (NO) bioavailability and increased reactive oxygen species (ROS) generation.
Methods. We examined epidemiological and clinical data linking cigarette smoking and ED, and the effects of
smoking on vascular NO bioavailability and ROS generation.
Main Outcome Measures. There are strong parallels between smoking and ED and considerable evidence support-
ing the concept that smoking-related ED is associated with reduced bioavailability of NO because of increased ROS.
Results. Cigarette smoking-induced ED in human and animal models is associated with impaired arterial flow to the
penis or acute vasospasm of the penile arteries. Long-term smoking produces detrimental effects on the vascular
endothelium and peripheral nerves and also causes ultrastructural damage to the corporal tissue, all considered to
play a role in chronic smoking-induced ED. Clinical and basic science studies provide strong indirect evidence that
smoking may affect penile erection by the impairment of endothelium-dependent smooth muscle relaxation or more
specifically by affecting NO production via increased ROS generation. Whether nicotine or other products of
cigarette smoke mediate all effects related to vascular damage is still unknown.
Conclusions. Smoking prevention represents an important approach for reducing the risk of ED. The character-
ization of the components of cigarette smoke leading to ED and the mechanisms by which these components alter
signaling pathways activated in erectile responses are necessary for a complete comprehension of cigarette smoking-
associated ED. Tostes RS, Carneiro FS, Lee AJ, Giachini FRC, Leite R, Osawa Y, and Clinton Webb R.
Cigarette smoking and erectile dysfunction: Focus on NO bioavailability and ROS generation. J Sex Med
2008;5:1284–1295.
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Physiology of Erection
P enile erection is determined by pressure chan-ges in the cavernosal sinuses. The vasculature
of the erectile tissue differs from most vascular beds
as it is composed of arterioles and hollow blood-
filled sinuses, both of which are lined with smooth
muscle and endothelial cells [1,2].
In the absence of arousal stimuli, cavernosal
vasoconstriction maintains the penis in the non-
erect state. Contraction of the cavernosal smooth
muscle, mainly in response to norepinephrine
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released from the sympathetic innervation of the
penis, narrows the arteriolar lumen and sinusoidal
cavities, restricting blood flow to maintain low
intracavernosal pressure (ICP) and a nonerect
(flaccid) penis [1,2]. During sexual arousal or noc-
turnal tumescence, the release of nitric oxide (NO)
(predominantly through the activation of nitric
oxide synthase [NOS] in nonadrenergic noncho-
linergic [NANC] nerves and local endothelial
cells) stimulates smooth muscle relaxation [1–3].
The resulting dilation of the cavernosal arterioles
and sinuses results in increased blood flow (driven
by the force of the arterial blood pressure) and a
subsequent rise in ICP. This initial rise in ICP
activates a veno-occlusive mechanism to limit the
outflow of blood and further increase the pressure
inside the cavernosum. The erectile response
ensues as the force of the elevated pressure
expands the outer tunica albuginea of the penis,
resulting in the increased penile length and diam-
eter characteristic of erection.
Although various vasodilators, such as acetyl-
choline and vasoactive intestinal peptide, have
been implicated in the erectile response, NO is
thought to be the principal stimulator of cavern-
osal vasodilation and penile erection. [3,4]. NO
is formed from the precursor amino acid,
L-arginine, by enzymatic action of NOS, which
exists as three main isoforms: neuronal NOS
(nNOS), inducible (iNOS), and endothelial NOS
(eNOS). All three isoforms have been detected in
the penis, although nNOS and eNOS are the main
constitutively active NOS enzymes expressed in
penile tissues. nNOS is found in the cavernous
nerves and their terminal endings within the
corpora cavernosa, as well as in the branches of
the dorsal penile nerves and nerve plexuses in the
adventitia of the deep cavernous arteries [4,5].
eNOS is largely found in the endothelial cells cov-
ering the cavernous spaces and helicine arteries,
but not in the trabecular smooth muscle cells [6].
Endothelium-derived NO, largely generated in
response to strain forces brought on by increased
blood flow and pressure in the penis, is believed to
sustain the erectile process and, in some specific
conditions, may even guarantee erectile function
in the absence of nNOS [7]. Upon its release, NO
diffuses locally into adjacent smooth muscle cells
of the corpus cavernosum and binds to soluble
guanylyl cyclase, which catalyzes the conversion of
guanosine trisphosphate to 3′,5′-cyclic guanosine
monophosphate (cGMP). This cyclic nucleo-
tide then activates protein kinase G, also known
as cGMP-dependent protein kinase I, which
decreases cytosolic calcium (Ca2+) by various
mechanisms. The decay in cytosolic Ca2+ concen-
tration induces relaxation of the vascular and cav-
ernosal smooth muscle cells, leading to dilation of
arterial vessels, increased blood flow into the
sinuses of the corpora cavernosa, and penile
erection [7,8].
Erectile Dysfunction and Smoking
Epidemiological and Clinical Data
Erectile dysfunction (ED), defined as the inability
to attain and/or maintain penile erection [9], is a
multifactorial condition that is estimated to affect
more than 150 million men worldwide, with this
number expected to double by 2025 [10,11]. Con-
sidered a major public health problem, which seri-
ously affects the quality of life of patients and their
partners, ED becomes increasingly prevalent with
age. In addition, the presence of chronic illness
(e.g., heart disease, hypertension, and diabetes
mellitus), alcohol or drug abuse, sedentary lif-
estyle, and smoking are major risk factors for ED
[10,11].
Data from the 2003 National Health Interview
Survey (NHIS) indicated that approximately
21.6% of adults in the United States are current
smokers [12]. Although the percentage is much
lower than that reported in other countries (e.g., in
China, in 2000, 60.2% of men and 6.9% of women
aged 35–74 years are current smokers [13]), and
the prevalence is lower than that reported in 2001
and 2002, the rate of decline is not sufficient to
meet the National Health Service objective for
2010 (12%). In addition, an increase in smoking
among adolescents was reported [14].
While it is clear that ED is multifactorial, the
direct and negative effects of smoking on erectile
function are well documented. Several epidemio-
logical studies have shown that cigarette smoking
not only increases the risk of ED, but also ampli-
fies the risk of ED associated with other risk
factors (e.g., hypertension, diabetes, and dyslipi-
daemia) or with aging [10,15–25].
Epidemiological data linking cigarette smoking
and ED has been collected worldwide. In the
United States, the Massachusetts Male Aging
Study, which evaluated ED in men aged 40–70
years, indicated that cigarette smoking almost
doubled the likelihood of moderate or complete
ED at up to 10 years of follow-up [26]. In addition,
a study of veterans from the Vietnam-era, aged
31–49 years, showed that a higher percentage of
smokers reported ED problems in comparison to
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nonsmokers [15]. It has also been shown that the
magnitude of the association between smoking and
ED decreases across increasingly older age groups,
suggesting that smoking may have a more appar-
ent impact on erectile function in young male
smokers than it does in older male smokers [27].
The greater magnitude of association between
smoking and ED in young men is quite interesting
because other traditional causes of ED are not as
prevalent in this group as compared with older age
groups. Importantly, this study also showed that
pack-years of smoking is significantly associated
with ED in former and current smokers [27].
Similar findings have been reported by studies
conducted in other populations: Turkey [20],
Brazil [21], Italy [21,22], Japan [21], Malaysia [21],
Australia [24], Belgium [28], Netherlands [29],
China [30], Canada [31], Finland [32], and the
United Kingdom [33].
Many of these studies were conducted among
patients with established cardiovascular diseases
(atherosclerosis, diabetes, and hypertension).
However, a study including 7,684 Chinese men,
aged 35–74 years, showed that smoking is also
associated with ED in men without clinical vascu-
lar disease [30]. The increased odds ratio of ED
was directly correlated with the number of ciga-
rettes smoked per day and the association between
smoking and ED was even stronger in participants
with diabetes [30].
A very recent report, the Boston Area Com-
munity Health (BACH) survey, has shown that
although the association between passive smoking
and ED is not statistically significant, the magni-
tude of the effect of passive smoking is comparable
to 10–19 pack-years of smoking exposure [34]. A
previous study showed that men exposed to passive
smoking are at twice the risk of developing ED
over a 9-year follow-up period [26]. These results
suggest that although the increased risk in ED
with passive smoking is small, long-term chronic
exposure to passive smoking may have adverse
effects on erectile function. Importantly, second-
hand smoking or passive smoking also increases
the risk of heart disease (by approximately 30%)
and adversely affects vascular function [35].
Despite the fact that the dose of smoke delivered
to active smokers is 100 times or more than that
delivered to a passive smoker, the relative risk of
cardiovascular disease for smokers is 1.78 com-
pared with 1.31 for passive smokers. In many cases,
the effects of even brief (minutes to hours) passive
smoking are nearly as large as those from chronic
active smoking. Passive smoking leads to 68–86%
of the risk of light smoking, depending on the level
of secondhand smoke exposure [35].
Cigarette smoking-induced ED in human and
animal models has been associated with impaired
arterial flow to the penis or acute vasospasm of the
penile arteries. The relative risk of developing ath-
erosclerosis in the penis and subsequent ED is 1.31
for each 10 pack-years smoked [17] and 86% of
smokers have an abnormal penile vascular evalua-
tion [16]. Furthermore, penile rigidity during
nocturnal erection inversely correlates with the
number of cigarettes smoked per day [18]. The
effects of smoking on the vascular endothelium
[36–39] and peripheral nerves [40,41] have been
considered to play a role in chronic smoking-
induced ED. Furthermore, long-term smoking
causes ultrastructural damage to the corporal
tissue and increases vascular stiffness [42].
Smoking, NO, and Oxidative Stress
As NO is thought to be the principal stimulator of
cavernosal relaxation and penile erection [3,4],
smoking- or cigarette-induced decreases in the
synthesis or availability of NO may lead to ED. An
insufficient synthesis of NO, leading to impaired
corporal smooth muscle relaxation, occurs in
either of two ways: (i) endothelial damage leading
to reduced activity and/or down-regulation of
eNOS; or (ii) decrease in the activity or levels
of the penile nNOS. Accordingly, studies from
several laboratories and clinical trials have demon-
strated that both acute and chronic smoking cause
impairment of NO production [36–38,43–48].
Most of these studies have addressed the effects of
smoking on NO produced by eNOS activation or
NO derived from the endothelial cells.
It is known that tobacco smoke has direct detri-
mental effects on endothelial cells, causing archi-
tectural and functional changes (Figure 1). These
include decreased eNOS activity, impaired
endothelium-dependent vasorelaxation, increased
expression of cell adhesion molecules and transen-
dothelial migration of monocyte-like cells, reduced
response to vascular endothelial growth factor, and
impaired regulation of important thrombotic
factors [37,43–53]. In humans and animal models,
cigarette smoke or products of cigarette smoke
produce diffuse vascular injury in many organ
systems and impair eNOS-dependent dilatation of
large peripheral arteries and resistance arterioles.
Furthermore, chronic smoking also modifies the
functional properties of medial elastic fibers by
promoting changes in the viscoelastic properties of
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the extracellular matrix and by inducing calcifica-
tion of the medial elastic fibers [54,55].
Although the effects of smoking on endothe-
lial cells/eNOS are well established, much less
information exists regarding the effects of smoking
on nNOS-mediated penile erection. However, in
rats, both at the age of 5 or 20 months, prolonged
exposure to cigarette smoke reduces neuronal (not
endothelial) NOS activity and content in the
penis, but not in the cerebellum [56]. Interestingly,
prenatal exposure to cigarette smoke induces loss
of nNOS protein in the brainstem of neonatal rats
[57]. In addition, a very recent report has shown
that acute exposure to nicotine impairs nNOS-
dependent reactivity of cerebral arterioles by a
mechanism that appears to be related to the for-
mation of superoxide anion [58].
Contradictory results have been shown regard-
ing the effects of cigarette smoking on iNOS activ-
ity and expression. Whereas cigarette smoke
condensates attenuate cytokine induction of iNOS
protein expression and endogenous enzymatic
nitrite production in glioma cells [59], and in
murine and human lung epithelial cell lines (LA-4
and A549, respectively) [60], cigarette smoke
increases iNOS expression, as well as nuclear
factor kappa B and c-fos, in rat lung tissue [61].
Similarly, nicotine has been shown to potentiate
lipopolysaccharide/interferon-gamma-induced cy-
totoxic effects by enhancing NO production and
iNOS gene expression, suggesting a cross-talk
between inflammation and smoking [62].
As cigarette smoke contains superoxide and
other reactive oxygen species (ROS), it has been
hypothesized that some of the adverse effects of
smoking may result from oxidative damage to
endothelial cells, which results in NO shortage [63]
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Figure 1 Mechanisms involved in cigarette-induced vascular injury.
NO is thought to be the principal stimulator of cavernosal relaxation and penile erection. There is considerable evidence
supporting the concept that smoking-related ED is associated with reduced bioavailability of NO because of increased ROS.
For details, see text.
Ach = acetylcholine; cGMP = 3′,5′-cyclic guanosine monophosphate eNOS, endothelial nitric oxide synthase; M3 = type 3
muscarinic receptor; MLC = myosin light chain; nNOS = neuronal nitric oxide synthase; NO = nitric oxide; ROCK = Rho-
associated kinase; ROS = reactive oxygen species.
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molecules, are generated by many enzymes, but
mainly by NOX enzymes (NADPH oxidases; nico-
tinamide adenine dinucleotide phosphate-oxidase)
[64,65]. ROS avidly interact with a large number of
molecules including other small inorganic mol-
ecules as well as proteins, lipids, carbohydrates, and
nucleic acids. Through such interactions, ROS may
irreversibly destroy or alter the function of the
target molecule. Consequently, ROS have been
increasingly identified as major contributors to
damage in biological organisms. The antagonistic
effect of ROS on the NO pathway is partially attrib-
uted to the fast reaction of superoxide with NO to
produce peroxynitrite, thereby decreasing NO
levels. Other mechanisms, including NOS uncou-
pling and inhibition of dimethylarginine dimethy-
laminohydrolase (DDAH), may also contribute to
ROS-mediated shortage of NO levels [63–65].
Accordingly, increased inactivation of NO by
superoxide results in impaired penile NO transmis-
sion and smooth muscle relaxation [66–68].
Smoking disrupts the dynamic balance between
oxidation and antioxidation reactions and clearly
exacerbates oxidative stress [52,69–76] (Figure 1).
Smoking (or specific compounds of cigarette
smoke) increases superoxide generation by both
endothelial and smooth muscle cells, impairs
acetylcholine-induced relaxation of arteries, in-
creases mRNA expression of pro-inflammatory
cytokines, such as interleukin-1 beta, interleukin-6,
and tumor necrosis factor-alpha, all effects
prevented by inhibition of NAD(P)H oxidase or
by treatment with antioxidants [74–76]. As tetra-
hydrobiopterin (BH4) supplementation improves
endothelial dysfunction in chronic smokers, it is
accepted that, in addition to the free radical burden
of cigarette smoke, a dysfunctional eNOS because
of BH4 depletion contributes to endothelial dys-
function in chronic smokers [77–80]. In addition,
cigarette smoking causes increased production of
cyclooxygenase dependent and independent vaso-
constrictor eicosanoids [79].
Interestingly, smoking activates Rho-associated
kinase (ROCK) in forearm vascular smooth
muscle cells,[81] and increased oxidative stress has
also been associated with increased ROCK activity
and vascular stiffness in humans [82]. In healthy
male subjects, age and number of pack-years
smoked are independent predictors of ROCK
activity, suggesting that aging and accumulating
smoking habit, which might induce excessive oxi-
dative stress, are involved in ROCK activity in the
vasculature [82]. The importance of ROCK in the
Ca2+ sensitization of corpus cavernosum smooth
muscle cells and maintenance of penile flaccidity is
well recognized [8,83,84].
Further evidence that oxidative stress, mediated
through the superoxide radical (superoxide) and
other ROS, may be central to impaired cavernosal
function in ED, include: (i) cavernosal vascular
smooth muscle cells generate superoxide in
response to a variety of stimuli, including nicotine,
and mechanical injury [66–68]; (ii) oxidative stress,
induced by inhibition of endogenous Cu/Zn
superoxide dismutase (SOD) with diethyldithio-
carbamate and a superoxide anion generator, in
bovine retractor penis muscle strips, results in
almost complete inhibition of nitrergic relaxation
[85]; (iii) ED associated with pathological condi-
tions, such as hypercholesterolaemia and diabetes,
is accompanied by augmentation of NADPH
oxidase-derived superoxide in the cavernosal tissue
[86–88]; and (iv) treatment of diabetic animals
with antioxidants or oxygen free radical scaven-
gers, improves erectile function, enhances levels
of circulating NO, increases nNOS expression
and also enhances the therapeutic effect of the
phosphodiesterase-5 (PDE-5) inhibitor sildenafil
[88,89].
High concentrations of ROS, NO, peroxyni-
trite, peroxynitrate, and free radicals of organic
compounds are found in the two phases of
cigarette smoke: tar and gas-phase smoke [90]. In
addition to these short-lived, highly reactive sub-
stances, the gas phase of cigarette smoke contains
varying amounts of more stable substances that
also have the potential to increase intracellular
production of ROS [91]. These include a series of
a, b-unsaturated aldehydes, such as acrolein and
crotonaldehyde, a, b-unsaturated ketones, and a
number of saturated aldehydes [91]. These stable
compounds have been shown to react nonenzy-
matically with thiol groups that may be involved in
the regulation of enzymes, including NADPH
oxidase [92,93]. Furthermore, because of their sta-
bility, these compounds could induce ROS pro-
duction in vascular fields remote from the primary
site of exposure [92].
Another interesting aspect that should be con-
sidered is the association between smoking and
testosterone. Testosterone plays a major role in
men’s sexual function. Testosterone regulates not
only sexual activity and libido, but also cGMP
formation, through NOS stimulation, and its
catabolism, through PDE-5 activity [94,95].
Decreased plasma testosterone levels are associ-
ated with ED and studies in castrated animals
have proven that addition of testosterone, and
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its conversion to dihydrotestosterone, restores
erectile function [96]. In addition, late onset
hypogonadism (LOH), or testosterone deficiency
syndrome, is often associated with reduced sexual
desire and reduced nocturnal penile erections
[97]. Patients with LOH are less responsive to
treatment with PDE-5 inhibitors, but testo-
sterone replacement in these subjects restores
responsiveness to PDE-5 inhibitors [97]. Inter-
estingly, several studies have shown that testoster-
one levels are significantly increased in current
smokers [98–101]. Corona and colleagues have
recently confirmed an association between vascu-
lar ED and smoking, and also the presence of
higher testosterone levels in current smokers
[101]. Most of these reports have found a positive
correlation between testosterone levels and the
number of cigarettes smoked daily [98–100]. In
addition, in a longitudinal study with an 11-year
follow-up, men who quit smoking have an
increased risk of hypogonadism [99]. It is possible
that increased testosterone levels, which at a first
glance would suggest a more sexual-favorable
hormonal milieu, represent a compensatory
mechanism to the ultrastructural and functional
damage generated by smoking. Additional studies
are needed to clarify the relationship between
smoking, ED and testosterone.
Components Involved in the Effects of
Cigarette Smoking
Many of the vascular effects of chronic smoking
are attributed to nicotine, a tertiary amine com-
posed of a pyridine ring. Nicotine induces endo-
thelial dysfunction [102–104], which in dogs
depends on duration and dose of nicotine treat-
ment [104]. Nicotine-induced endothelial dys-
function has been associated with increased
plasma levels of asymmetric dimethylarginine
(ADMA), an endogenous NOS inhibitor and also
a risk factor for cardiovascular disease. Nicotine-
induced ADMA accumulation is related to a
decrease in activity of DDAH, a major hydrolase
of ADMA [102]. Whether nicotine or other prod-
ucts of cigarette smoke mediates all effects related
to vascular damage is still unknown.
Harten and Meston have recently reported that
nicotine significantly attenuates physiological
sexual arousal in healthy nonsmoking men [105].
However, the only report on the effects of smoking
on nNOS activity/expression has shown that nico-
tine is not responsible for the reduced nNOS
activity and content induced by passive cigarette
smoking [56]. Incubation of penile slices or rat
penile smooth muscle cells with nicotine or
conitine (the major nicotine metabolite) does not
change nitrite levels or nNOS activity [56]. Dr.
Osawa’s group has shown that aqueous extracts of
cigarette and cigarette smoke cause inactivation of
eNOS and nNOS [80,106–108]. By using an in
vitro system containing purified NOS isoforms,
they observed that aqueous extract of cigarette
or cigarette smoke inactivates nNOS in a time-
and metabolism-based manner. The compound
responsible for such effect is not nicotine and
seems to be a low molecular weight, nonvolatile,
cationic, organic molecule, found in an alkaloid-
containing fraction from tobacco (Nicotiana
tabacum) [106].
We have tested the effects of a water-soluble
extract made from cigarettes and an HPLC-
purified fraction of nonburned cigarettes on
isolated mouse cavernosal strips. Functional
responses that are mediated by activation of eNOS
and nNOS were addressed. The purified fraction
of cigarette extract (5%) inhibits electrical field
stimulation (EFS)-induced relaxation, which relies
on nNOS activation, but it does not interfere with
acetylcholine-induced relaxation, which relies
on eNOS-derived NO (Figure 2). To determine
relaxant responses to NANC nerve stimulation
(nNOS activation), strips were treated with the
sympathetic nerve-blocking agent bretylium tosy-
late (3 ¥ 10-5 M) and atropine (a muscarinic recep-
tor antagonist; 10-6 M) for 45 minutes, contracted
with phenylephrine (PE 10-5 M), and then EFS
(conducted at 50 V, 1-ms pulse width and trains of
stimuli lasting 10 seconds at varying frequencies [1
to 32 Hz]) was performed.
On the other hand, in vitro analyses have shown
that out of 4,800 different compounds in cigarette
smoke, the mixture of metals and oxidants is
crucial to produce endothelium damage [108].
Cigarette smoke contains a number of different
metals, including aluminum, cadmium, chromium,
copper, lead, mercury, nickel, and zinc. The com-
bination of metals and antioxidants leads to a chain
reaction of protein oxidation, functional impair-
ment of the microtubule system, contraction of
endothelial cells, endothelial dysfunction, and to
denudation of the inner vascular surface [108]. A
recent report has shown that smokers smoking
more than three cigarettes per day had signifi-
cantly increased serum levels of cadmium and
strontium compared with nonsmokers [109].
Although not significant, passive smokers and
study subjects smoking less than three cigarettes
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per day also showed increases in the concentration
of both metals [109].
As increased serum cadmium levels have been
shown to contribute to smoking-induced periph-
eral arterial disease [110], the deleterious effects of
cigarette smoking may be also related to changes
in body’s metal homeostasis.
Perspectives
Although cessation of cigarette smoking can
improve ED in a considerable proportion of
smokers, age and severity of ED before cessation
are inversely related to the chance of improve-
ment. Smoking prevention represents a very
important approach for reducing the risk of ED.
The characterization of the components of ciga-
rette smoke leading to ED, as well as a better
understanding of how these components alter sig-
naling pathways activated in erectile responses, are
necessary for a complete comprehension of ciga-
rette smoking-associated ED.
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Figure 2 Effects of cigarette extract
on EFS-induced relaxation of murine
cavernosal strips.
Representative tracing showing that
the HPLC-purified fraction of non-
burned cigarettes (5%) inhibits (A)
EFS-induced relaxation, which relies
on nNOS activation, but it did not inter-
fere with (B) acetylcholine-induced
relaxation, which relies on eNOS-
derived NO.
Ach = acetylcholine; EFS = electrical
field stimulation; PCE = purified frac-
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